A New Treatment Breakthrough for EGFR-mutated Lung Cancer
The chemotherapy-free combination of lazertinib and amivantamab has just been approved as first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC). In this interview, Consultant Seppo W. Langer discusses the mechanism of action, clinical benefits, and the need for patient selection in future treatment strategies.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
